PEOPLE - Changes at Cytogen:
This article was originally published in Clinica
Dr Thomas McKearn has stepped down from his role as chairman, president and CEO of Cytogen. Board member William Mills has been appointed to take on the role as chairman and John Bagalay will act as interim president and CEO in addition to his current role as interim CFO. The US company develops products for the targeted delivery of diagnostics and therapeutic substances to disease sites.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.